A Phase 2/3 observer-blind, randomized, controlled study to determine the safety and immunogenicity of SARS-CoV-2 recombinant spike protein vaccine in Indian children and adolescents aged 2 to 17 years

Bhagwat Gunale, Dhananjay Kapse, Sonali Kar, Ashish Bavdekar, Sunil Kohli, Sanjay Lalwani, Sushant Meshram, Abhishek Raut, Praveen Kulkarni, Clarence Samuel, Renuka Munshi, Madhu Gupta, Joyce Plested, Shane Cloney-Clarke, MingZhu Zhu, Melinda Pryor, Stephanie Hamilton, Madhuri Thakar, Ashwini Shete, Abhijeet Dharmadhikari, Chetanraj Bhamare, Umesh Shaligram, Cyrus S. Poonawalla, Raburn M. Mallory, Gregory M Glenn, Prasad S. Kulkarni, the COVOVAX-Ped Study Group
doi: https://doi.org/10.1101/2023.01.03.23284130

Data Availability

All data produced in the present work are contained in the manuscript.

Back to top
Posted January 19, 2023.
Download PDF
Data/Code
Email
A Phase 2/3 observer-blind, randomized, controlled study to determine the safety and immunogenicity of SARS-CoV-2 recombinant spike protein vaccine in Indian children and adolescents aged 2 to 17 years
Bhagwat Gunale, Dhananjay Kapse, Sonali Kar, Ashish Bavdekar, Sunil Kohli, Sanjay Lalwani, Sushant Meshram, Abhishek Raut, Praveen Kulkarni, Clarence Samuel, Renuka Munshi, Madhu Gupta, Joyce Plested, Shane Cloney-Clarke, MingZhu Zhu, Melinda Pryor, Stephanie Hamilton, Madhuri Thakar, Ashwini Shete, Abhijeet Dharmadhikari, Chetanraj Bhamare, Umesh Shaligram, Cyrus S. Poonawalla, Raburn M. Mallory, Gregory M Glenn, Prasad S. Kulkarni, the COVOVAX-Ped Study Group
medRxiv 2023.01.03.23284130; doi: https://doi.org/10.1101/2023.01.03.23284130
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area